Search Results | Cancer Research | American Association for Cancer Research

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Abstract 6594: Targeting Ewing sarcoma and osteosarcoma with anti-MCAM chimeric antigen receptor modified NK cells

Aliza Gardenswartz, Wen Luo, Jeremy M. Rosenblum, Janet Ayello, Mitchell S. Cairo

Cancer Res (2020) 80 (16_Supplement): 6594.

DOI: https://doi.org/10.1158/1538-7445.AM2020-6594

Published: 15 August 2020

View article

Journal Articles

Abstract 2381: Blinatumomab enhanced anti-tumor activity against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL)

Aradhana Awasthi Tiwari, Dina Edani, Janet Ayello, Mitchell S. Cairo

Cancer Res (2019) 79 (13_Supplement): 2381.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2381

Published: 01 July 2019

View article

Journal Articles

Abstract 3648: Protein phosphatase 1 regulatory subunit 1A regulates cell cycle progression in Ewing sarcoma

Wen Luo, Marcela Laukova, Sarah Phillips, Janet Ayello, Mitchell S. Cairo

Cancer Res (2019) 79 (13_Supplement): 3648.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3648

Published: 01 July 2019

View article

Journal Articles

Abstract 1537: Polatuzumab Vedotin alone or in-combination with anti-CD20 antibody significantly enhanced overall survival in xenografted NSG mice against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL)

Aradhana Awasthi Tiwari, Dina Edani, Janet Ayello, Christian Klein, Mitchell S. Cairo

Cancer Res (2019) 79 (13_Supplement): 1537.

DOI: https://doi.org/10.1158/1538-7445.AM2019-1537

Published: 01 July 2019

View article

Journal Articles

Abstract 1788: Enhanced in vitro/in vivo cytotoxicity against Burkitt lymphoma/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu- anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab

Aradhana Awasthi Tiwari, Dina Edani, Christeen Azmy, Janet Ayello, Christian Klein, Mitchell S. Cairo

Cancer Res (2018) 78 (13_Supplement): 1788.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1788

Published: 01 July 2018

View article

Journal Articles

Abstract 2565: EBV peptide-derived vaccine significantly enhanced in vitro cytotoxicity against EBV-positive B-cell lymphoma (EBV-BL) treatment using TMV-based delivery system

Aradhana Awasthi Tiwari, Alison McCormick, Dina Edani, Aaron Newman, Christeen Azmy, Janet Ayello, Christian Klein, Mitchell S. Cairo

Cancer Res (2018) 78 (13_Supplement): 2565.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2565

Published: 01 July 2018

View article

Journal Articles

Abstract 5817: Protein phosphatase 1 regulatory subunit 1A promotes tumorigenesis and metastasis in Ewing sarcoma

Wen Luo, Changxin Xu, Janet Ayello, Filemon De La Cruz, Jeremy Rosenblum, Stephen L. Lessnick, Mitchell S. Cairo

Cancer Res (2017) 77 (13_Supplement): 5817.

DOI: https://doi.org/10.1158/1538-7445.AM2017-5817

Published: 01 July 2017

View article

Journal Articles

Abstract 2656: Polatuzumab vedotin significantly enhances in vitro cell death and overall survival against CD79b+ Burkitt lymphoma (BL)/primary mediastinal large B-cell lymphoma (PMBL) NSG xenograft mice

Aradhana A. Tiwari, Janet Ayello, Christeen Azmy, Carmella van de Ven, Mitchell S. Cairo

Cancer Res (2017) 77 (13_Supplement): 2656.

DOI: https://doi.org/10.1158/1538-7445.AM2017-2656

Published: 01 July 2017

View article

Journal Articles

Abstract 2657: PD-L1 blockade enhances T cell cytotoxicity against primary mediastinal B cell lymphoma

Tishi Shah, Wen Luo, Aradhana Awasthi, Janet Ayello, Jessica Hochberg, Mitchell Cairo

Cancer Res (2017) 77 (13_Supplement): 2657.

DOI: https://doi.org/10.1158/1538-7445.AM2017-2657

Published: 01 July 2017

View article

Journal Articles

Abstract 2211: Enhanced in vitro and in vivo targeting of rituximab-sensitive and -resistant Burkitt lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR)-modified expanded natural killer cells in combination with a histone deacetylase inhibitor, romidepsin

Yaya Chu, Ashlin Yahr, Bokun Cheng, Bian Hang, Janet Ayello, Matthew Bath, Mitchell S. Cairo

Cancer Res (2016) 76 (14_Supplement): 2211.

DOI: https://doi.org/10.1158/1538-7445.AM2016-2211

Published: 15 July 2016

View article

Journal Articles

Abstract 3893: Obinutuzumab (GA101) versus rituximab against rituximab-sensitive and -resistant Burkitt lymphoma (BL) differentially phosphorylate BCR, Fc-gamma receptor, and natural killer cell-mediated cytotoxicity signaling pathways

Aradhana Awasthi Tiwari, Delphine C.m. Rolland, Mona Elmacken, Janet Ayello, Lisa Kurien, Carmella van de Ven, Venkatesha Basrur, Kevin Conlon, Damine Fermin, Matthew J. Barth, Christian Klein, Kojo S.j. Elenitoba-Johnson, Megan Lim, Mitchell S. Cairo

Cancer Res (2016) 76 (14_Supplement): 3893.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3893

Published: 15 July 2016

View article

Journal Articles

Abstract 3838: Upregulation of DLEU1 significantly prolongs survival in a rituximab-treated DLEU1 knockout human Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in pediatric BL

Sanghoon Lee, Changhong Yin, Tishi Shah, Janet Ayello, Erin Morris, Carmella van de Ven, Mitchell S. Cairo

Cancer Res (2016) 76 (14_Supplement): 3838.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3838

Published: 15 July 2016

View article

Journal Articles

Abstract 579: Antibody drug conjugates (anti-CD79b-vc-MMAE, Polatuzumab Vedotin) exhibit enhanced cell death targeted to CD79b+ Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL)

Aradhana Awasthi Tiwari, Janet Ayello, Carmella van de Ven, Lisa Kurien, Matthew J. Barth, Mitchell S. Cairo

Cancer Res (2016) 76 (14_Supplement): 579.

DOI: https://doi.org/10.1158/1538-7445.AM2016-579

Published: 15 July 2016

View article

Journal Articles

Abstract 544: Protein phosphatase 1 regulatory subunit 1A (PPP1R1A) promotes tumor growth and metastasis via inhibition of protein phosphatase 1 in Ewing sarcoma

Wen Luo, Changxin Xu, Janet Ayello, Filemon Dela Cruz, Jeremy Rosenblum, Stephen Lessnick, Mitchell S. Cairo

Cancer Res (2016) 76 (14_Supplement): 544.

DOI: https://doi.org/10.1158/1538-7445.AM2016-544

Published: 15 July 2016

View article

Journal Articles

Abstract 4913: Engineering dendritic cell-based vaccines as targeted immunotherapy against medulloblastoma, neuroblastoma, and Ewing sarcoma

Stacey Zahler, Wen Luo, Janet Ayello, Mitchell S. Cairo

Cancer Res (2016) 76 (14_Supplement): 4913.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4913

Published: 15 July 2016

View article

Journal Articles

Abstract 2479: Obinutuzumab compared to Rituximab significantly enhances cell death, antibody dependent cytotoxicity (ADCC) and improves overall survival against CD20⁺ rituximab-sensitive/-resistant Burkitt Lymphoma (BL) and precursor Lymphoblastic L

Aradhana Awasthi Tiwari, Janet Ayello, Carmella Vandeven, Mona Elmacken, Matthew J. Barth, Christian Klein, Mitchell S. Cairo

Cancer Res (2015) 75 (15_Supplement): 2479.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2479

Published: 01 August 2015

View article

Journal Articles

Abstract 2608: Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL

Sanghoon Lee, Changhong Yin, Timmy O'Connell, Matthew Barth, Janet Ayello, Lauren Harrison, Carmella van de Ven, Rodney Miles, Paul Galardy, Stanton C. Goldman, Megan Lim, Michelle Hermiston, Linda McAllister-Lucas, Lisa G. Roth, Sherrie L. Perkins, Mitchell S. Cairo

Cancer Res (2015) 75 (15_Supplement): 2608.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2608

Published: 01 August 2015

View article

Journal Articles

Abstract 2077: DLEU1 significantly alters programmed cell death in chemoimmunotherapy-treated TALENs-induced DLEU1 knockout and DLEU1 overexpressing Burkitt Lymphoma (BL): DLEU1 may act as a tumor suppressor gene in pediatric BL

Sanghoon Lee, Changhong Yin, Janet Ayello, Carmella van de Ven, Mitchell S. Cairo

Cancer Res (2015) 75 (15_Supplement): 2077.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2077

Published: 01 August 2015

View article

Journal Articles

Abstract 3155: Neuroblastoma (NB), Medulloblastoma (MB), and Ewing's sarcoma (ES) express ROR1 and can be effectively targeted with NK cells modified to express an anti ROR1 chimeric antigen receptor (CAR)

Mona Elmacken, Aradhana Awasthi, Janet Ayello, Carmella VanDeVen, Wen Luo, Yanling Liao, Stanley Riddell, Mitchell S. Cairo

Cancer Res (2015) 75 (15_Supplement): 3155.

DOI: https://doi.org/10.1158/1538-7445.AM2015-3155

Published: 01 August 2015

View article

Journal Articles

Abstract 2902: Obinutuzumab (GA101) significantly increases overall survival against CD20+ rituximab-sensitive and -resistant Burkitt (BL) and acute lymphoblastic leukemia (B-ALL): potential targeted therapy in patients with high risk BL and pre-B-ALL

Aradhana A. Tiwari, Janet Ayello, Carmella van de Ven, Matthew J. Barth, Mitchell S. Cairo

Cancer Res (2014) 74 (19_Supplement): 2902.

DOI: https://doi.org/10.1158/1538-7445.AM2014-2902

Published: 01 October 2014

View article

NARROW

Abstract 6594: Targeting Ewing sarcoma and osteosarcoma with anti-MCAM chimeric antigen receptor modified NK cells

Abstract 2381: Blinatumomab enhanced anti-tumor activity against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL)

Abstract 3648: Protein phosphatase 1 regulatory subunit 1A regulates cell cycle progression in Ewing sarcoma

Abstract 1537: Polatuzumab Vedotin alone or in-combination with anti-CD20 antibody significantly enhanced overall survival in xenografted NSG mice against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL)

Abstract 1788: Enhanced in vitro/in vivo cytotoxicity against Burkitt lymphoma/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu- anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab

Abstract 2565: EBV peptide-derived vaccine significantly enhanced in vitro cytotoxicity against EBV-positive B-cell lymphoma (EBV-BL) treatment using TMV-based delivery system

Abstract 5817: Protein phosphatase 1 regulatory subunit 1A promotes tumorigenesis and metastasis in Ewing sarcoma

Abstract 2656: Polatuzumab vedotin significantly enhances in vitro cell death and overall survival against CD79b+ Burkitt lymphoma (BL)/primary mediastinal large B-cell lymphoma (PMBL) NSG xenograft mice

Abstract 2657: PD-L1 blockade enhances T cell cytotoxicity against primary mediastinal B cell lymphoma

Abstract 2211: Enhanced in vitro and in vivo targeting of rituximab-sensitive and -resistant Burkitt lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR)-modified expanded natural killer cells in combination with a histone deacetylase inhibitor, romidepsin

Abstract 3893: Obinutuzumab (GA101) versus rituximab against rituximab-sensitive and -resistant Burkitt lymphoma (BL) differentially phosphorylate BCR, Fc-gamma receptor, and natural killer cell-mediated cytotoxicity signaling pathways

Abstract 3838: Upregulation of DLEU1 significantly prolongs survival in a rituximab-treated DLEU1 knockout human Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in pediatric BL

Abstract 579: Antibody drug conjugates (anti-CD79b-vc-MMAE, Polatuzumab Vedotin) exhibit enhanced cell death targeted to CD79b+ Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL)

Abstract 544: Protein phosphatase 1 regulatory subunit 1A (PPP1R1A) promotes tumor growth and metastasis via inhibition of protein phosphatase 1 in Ewing sarcoma

Abstract 4913: Engineering dendritic cell-based vaccines as targeted immunotherapy against medulloblastoma, neuroblastoma, and Ewing sarcoma

Abstract 2479: Obinutuzumab compared to Rituximab significantly enhances cell death, antibody dependent cytotoxicity (ADCC) and improves overall survival against CD20⁺ rituximab-sensitive/-resistant Burkitt Lymphoma (BL) and precursor Lymphoblastic L

Abstract 2608: Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL

Abstract 2077: DLEU1 significantly alters programmed cell death in chemoimmunotherapy-treated TALENs-induced DLEU1 knockout and DLEU1 overexpressing Burkitt Lymphoma (BL): DLEU1 may act as a tumor suppressor gene in pediatric BL

Abstract 3155: Neuroblastoma (NB), Medulloblastoma (MB), and Ewing's sarcoma (ES) express ROR1 and can be effectively targeted with NK cells modified to express an anti ROR1 chimeric antigen receptor (CAR)

Abstract 2902: Obinutuzumab (GA101) significantly increases overall survival against CD20+ rituximab-sensitive and -resistant Burkitt (BL) and acute lymphoblastic leukemia (B-ALL): potential targeted therapy in patients with high risk BL and pre-B-ALL

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only